spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Myelodysplastic Syndromes 

 HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Oct 2019
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Aug 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jul 2019
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Feb 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Dec 2018
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 16 Aug 2018
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 5 Feb 2018
Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Sep 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Aug 2015
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jan 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2014
Aileron Therapeutics Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Nov 2013
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2013
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2013
Teva’s Lonquex(R)(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Mar 2013
Acceleron Receives Two FDA Orphan Designations for ACE-536
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2012
Array BioPharma Names Howard Holden, Ph.D., Vice President of Regulatory Affairs and Quality Assurance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2011
Optimer Pharmaceuticals Announces Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2010
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2010
Alexion's Soliris(R) (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Apr 2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Oct 2008
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Aug 2008
FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Aug 2008
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jul 2008
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2008
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2008
VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jun 2008
Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Mar 2008
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
 HSMN NewsFeed - 19 Feb 2008
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2008
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2008
Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jan 2008
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2007
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2007
Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2007
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2007
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Nov 2007
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Sep 2007
CombiMatrix Molecular Diagnostics Launches HemeScan MDS for the Management and Diagnosis of Myelodysplastic Syndromes
Diagnostics Oncology
 HSMN NewsFeed - 11 Sep 2007
Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2007
Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2007
INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 5 Sep 2007
Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 29 Aug 2007
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 20 Aug 2007
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2007
Alexion's Soliris(TM) Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jun 2007
Studies Show Efficacy and Safety of Alexion's Soliris(TM) in Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2007
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jan 2007
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Nov 2006
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Nov 2006
CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2006
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Nov 2006
Pharmion Corporation Announces Enrollment of First Patient Into Vidaza(R) Patient Registry
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2006
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2006
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 May 2006
MGI PHARMA Announces Commercial Availability of Dacogen(TM) (Decitabine) for Injection
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 81

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 81 additional stories matching:
Myelodysplastic Syndromes
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.